Wow.!!! Prostate cancer, Can Now Be Cured with high dose Of Testosterone Jabs. "Big Medical Breakthrough"...

PROSTATE cancer could be treated by shocking tumours with testosterone after a man with the advanced stage of the disease was cured.
Scientists have been surprised by the results of the trial  as the male hormone is generally assumed to fuel cancer. Tumours were seen to shrink and in several patients also suffering with the cancer, the progress of the tumours slowed down and even stopped.

Levels of Prostate Specific Antigen (PSA), a marker used to monitor prostate cancer, fell in the majority of the 47 participants.

One individual whose PSA levels dropped to zero after three months and shows no remaining trace of the disease after 22 cycles of treatment appears to be cured, said the researchers.

Professor Sam Denmeade, from Johns Hopkins University School of Medicine in Baltimore, US, who led the new study, described the results as ‘unexpected and exciting’. "We are still in the early stages of figuring out how this works and how to incorporate it into the treatment paradigm for prostate cancer,” he said. "Thus far we have observed dramatic PSA response in a subset of men; PSA levels declined in about 40 per cent of men and in about 30 per cent of men levels fell by more than 50 per cent.

"Some men also have objective responses with a decrease in the size of measurable disease, mostly in lymph nodes. Many of the men have stable disease that has not progressed for more than 12 months.

"I think we may have cured one man whose PSA dropped to zero after three months and has remained so now for 22 cycles. His disease has all disappeared." All the men taking part in the pilot trial had completed at least three cycles of BAT therapy, which involves flooding and starving the body of the male hormone testosterone. Experts said that for years men with advanced prostate cancer have been treated by cutting off or blocking the supply of testosterone.

However, the trials have shown shocking the tumours with high levels of the hormone can kill the cancer. The men received high dose injections of testosterone once every 28 days. At the same time, they were given a drug that stopped testosterone being produced naturally by the testicles.

Professor Denmeade added, ”Our goal is to shock the cancer cells by exposing them rapidly to very high followed by very low levels of testosterone in the blood. Six of the men tested positive for a protein called AR-V7 that may be associated with resistance to one of the cancer treatments. After BAT treatment, no sign of the protein was seen in the blood of all six. Two of the men had declines in PSA level of 50 per cent or more. Experts said the therapy appears to be well-tolerated by the patients, one man experiencing an increase in pain and another having a problem with urine retention.

Professor Denmeade said it was still not clear how the treatment worked, but it appeared to involve cell signalling and part of the process of cell division.

However, the expert warned that the therapy was still highly experimental and only suitable for men not suffering painful symptoms. "Testosterone treatment can definitely worsen pain in men with prostate cancer who have pain from their disease," he said. Each year around 47,000 men are diagnosed with prostate cancer in the UK and 11,000 die from the disease. Dr Matt Hobbs, deputy director of research at the charity Prostate Cancer UK, said: "Drugs that reduce the levels of testosterone (androgen deprivation therapy) are an effective treatment for thousands of men with advanced prostate cancer. "However, at some point the cancer evolves and those drugs stop working. “This research is intriguing because it offers a hint that - somewhat unexpectedly - for some men whose cancers have reached that 'hormone-resistant' stage it may be possible to kill or stop growth of the cancer cells by actually overloading them with testosterone. "Many exciting new lines of attack against prostate cancer are emerging of which this is one.”

However, Dr Hobbs warned the findings were from the early stages of research, adding further studies are needed to understand the ‘intriguing developments’.